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GAPDH is a classical glycolytic enzyme that has recently been demonstrated to
play critical roles outside of glycolysis.  These multifunctional roles include the ability
for GAPDH to function in DNA repair, membrane fusion, cytoskeletal dynamics, and cell
death.  These acquired multifunctional roles of are largely dictated by its subcellular
localization or by posttranslocation modifications that push GAPDH from the cytoplasm
to various subcellular niches.  Among several posttranslational modifications, oxidation
of GAPDH at C150 is one of the most well characterized modifications that have
established GAPDH as a sensor of oxidative stress.   In the presence of oxidative stress,
oxidation of GAPDH mediates its translocation to the nucleus, via Siah1, where it
mediates a stress response, cell death or cellular dysfunction in a “gain-of-toxic function”
manner.  Recently, an increasing number of studies have demonstrated that nuclear
translocation of GAPDH plays an underlying role in the manifestation of disease, such as
in, cancer, cardiovascular disease, neurodegeneration, ischemia and major mental illness.
Although the oxi-GAPDH stress-signaling cascade is well characterized, whether other
molecules can regulate this signaling cascade remains poorly understood.  This thesis will
focus on the GAPDH-Siah1 stress-signaling cascade and identifies a novel regulator.
Chapter I provides an overview of the multifunctional roles of GAPDH within distinct
subcellular domains, its medical implications and future perspectives.  Chapter II
identifies both ASK1 as regulator of the GAPDH-Siah1 stress-signaling cascade and
Siah1 as a novel substrate of ASK1.  We show that phosphorylation of Siah1 by ASK1
induces nuclear translocation of GAPDH and p300 acetylation.  In Chapter III, we
conclude that ASK1 and Siah1 might be potential therapeutic targets to regulate the
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GAPDH-Siah1 stress-signaling cascade in disease.
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Chapter I: The diverse functions of GAPDH: views from different subcellular
compartments
This Chapter was originally published in:
The diverse functions of GAPDH: views from different subcellular compartments.
Carlos Tristan, Neelam Shahani, Thomas W. Sedlak and Akira Sawa. Cellular
Signalling. 23 (2011) 317.
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Abstract
Multiple roles for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) have
been recently appreciated.  In addition to the cytoplasm where the majority of GAPDH is
located under basal conditions, GAPDH is also found in particulate fractions, such as the
nucleus, the mitochondria, and small vesicular fractions.  When cells are exposed to
various stressors, dynamic subcellular re-distribution of GAPDH occurs.  Here we review
these multifunctional properties of GAPDH, especially linking them to its
oligomerization, posttranslational modification, and subcellular localization.  This
includes mechanistic descriptions of how S-nitrosylation of GAPDH under oxidative
stress may lead to cell death/dysfunction via nuclear translocation of GAPDH, which is
counteracted by a cytosolic GOSPEL.  GAPDH is also involved in various diseases,
especially neurodegenerative disorders and cancers.  Therapeutic strategies to these
conditions based on the molecular understanding of GAPDH are discussed.
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Introduction
 In the past two decades, the glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) that was once considered a simple “housekeeping” protein has
been shown to be involved in many cellular processes in addition to glycolysis.  These
include: DNA repair (1), tRNA export (2), membrane fusion and transport (3,4),
cytoskeletal dynamics (5), and cell death (6-12).  The multifunctional properties of
GAPDH are likely to be regulated, at least in part, by its oligomerization,
posttranslational modification, and subcellular localization.  Posttranslational
modifications are divided into reversible and irreversible ones.  Here we review this
multifunctional nature of GAPDH exhibited in distinct subcellular domains of the
cytoplasm, vesicles, mitochondria, and nucleus.  We propose a novel concept of how
these functions may have a common biological significance in the role of stress response.
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1. GAPDH in the cytoplasm
In the cytoplasm GAPDH exists primarily as a tetrameric isoform composed of
four identical 37 kDa subunits, each with a single catalytic thiol group.  GAPDH coverts
glyceraldehyde-3-phosphate to D-glycerate 1,3-bisphospate, in the presence of
nicotinamide adenine dinucleotide (NAD+) and inorganic phosphate, and mediates
formation of NADH and adenosine triphosphate (ATP).  While GAPDH continues to
retain its fundamental role as a glycolytic “housekeeping” protein of the cytoplasm,
accumulating evidence indicates that posttranslational modifications of cytosolic GAPDH
regulate it’s glycolytic activity or push this molecule into functional avenues that deviate
from glycolysis.
Protein acetylation, a reversible posttranslational modification involved in
regulation of many cellular processes, has been reported to regulate cytosolic GAPDH
glycolytic activity (13).  In the presence of high glucose levels, acetylation of GAPDH at
lysine 254 (K254) via acetyltransferase p300/(CREB-binding protein)-associated factor
(PCAF) augments GAPDH enzymatic activity.  In contrast, low glucose levels repress
GAPDH glycolytic activity by histone deacetylase 5 (HDAC5) mediated deacetylation of
the K254 residue on GAPDH (13).  This study suggests that regulation of GAPDH
activity by PCAF and HDAC5 plays an important role in cancer cells that rely on aerobic
glycolysis to coordinate cellular process required for cell proliferation and tumor growth.
In human monocytes GAPDH facilitates a metabolic shift from anaerobic
respiration to the pentose phosphate pathway (14).  Oxidative stress following the
respiratory burst during phagocytosis and monocyte activation induces S-thiolation of the
reactive sulfhydryl groups on GAPDH.  The corresponding cysteine residue of GAPDH
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in other organisms is also modified under oxidative stress, which was proposed to be a
mechanism to protect the glycolytic enzyme from irreversible oxidative inactivation
(15,16).  Since inactivation of GAPDH by S-thiolation is readily reversible, this
posttranslational modification may allow GAPDH to function as a switch that enables
cells to shift between metabolic functions and maintenance of oxidation/reduction
balance.  Indeed, Krobitsch and colleagues (17) provided the first direct evidence that
oxidative inhibition of glycolytic enzymes, including GAPDH, is a controlled response
that enables cells to redirect their carbohydrate flux from glycolysis to the pentose
phosphate pathway, generating NADPH, the reducing power within cells to protect them
from oxidative stress (Fig. 1).
Other studies have shown that with the redox-sensitive cysteine residue 150,
GAPDH can modulate cellular signaling pathways in response to oxidative stress (18,19).
For example, GAPDH was shown to physiologically bind to inositol 1,4,5-trisphosphate
receptor, this association allows GAPDH to deliver NADH in close proximity to the
channel and thus regulates intracellular Ca2+ signaling (Fig. 1) (20).
S-Nitrosylation, a covalent addition of a nitric oxide (NO) group to the thiol side
chain of cysteine, has emerged as an important mechanism for reversible posttranslational
regulation of many proteins including GAPDH (21).  However, its effect in mediating a
metabolic flux is limited due to subsequent posttranslational modifications that inactivate
GAPDH irreversibly.  These include NAD+ or NADH attachment, both of which are
capable of more strongly inhibiting the catalytic activity of GAPDH (22,23).  When the
cell is exposed to massive stressors beyond its stress tolerance level, the inactivation of
GAPDH may have catastrophic “loss of function” effects by reducing the ability of the
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cell to meet the increased energy demands required to maintain homeostasis under
extreme stress (24,25).  However, posttranslational or conformational modifications to a
small pool of the total cellular GAPDH are potentially unlikely to induce dramatic
changes in the cellular glycolytic pathways.  For example, when a small pool of S-
nitrosylated GAPDH is further and irreversibly sulphonated (Fig. 1), this modification
facilitates the translocation of GAPDH to subcellular domains where it does not normally
occur and does not significantly impact the metabolic state of the cell.  As seen with
GAPDH-seven in absentia homolog 1 (Siah1) association, nuclear translocation of
GAPDH may stimulate a “gain of function” that could provoke apoptosis or cellular
dysfunction (see in subsection 5 below) (6).
The posttranslational modifications from S-nitrosylation to sulphonation commit
GAPDH to an irreversible signaling cascade that begins in the cytosol and traverses to
other cellular compartments.  Thus, regulatory mechanisms for this cascade are important
for cellular homeostasis.  We have recently reported a novel protein, GOSPEL
(GAPDH’s competitor Of Siah Protein Enhances Life), as a key regulator for GAPDH
(26).  This cytosolic protein is highly expressed in organs with high levels of energy
requirement and high expression levels of GAPDH, such as muscle, heart, and brain.  In
the presence of nitrosative stress, GOSPEL is quickly S-nitrosylated and retains GAPDH
in the cytoplasm, promoting GAPDH-GOSPEL association while competitively
preventing the cytotoxic interaction of GAPDH with Siah1 (Fig. 1) (26).  The
competition between GOSPEL and Siah1 for GAPDH binding is likely to maintain
cellular homeostasis when cells are exposed to stressors, by favoring the cytoprotective
GOSPEL S-nitrosylation over the cytotoxic mechanisms mediated by GAPDH S-
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nitrosylation.  However, once the level of nitrosative stress exceeds a threshold, GAPDH-
Siah1 binding predominates over GAPDH-GOSPEL interaction and then leads to cell
death/dysfunction (26).  This is analogous to S-nitrosylation of the NMDA-type
glutamate receptor (27-29): activation of NMDA receptor at a modest level contains a
protective mechanism by S-nitrosylation (a type of negative feedback), inhibiting the
overactivation of this receptor that might result in massive activation of nNOS
(nitrosative stress) and cell death/dysfunction.  Likewise, we reported that overexpression
of GOSPEL is neuroprotective, whereas mutant GOSPEL lacking the S-nitrosylation site
and its binding of GAPDH fails to block cell death in primary neuron cultures (26).  This
neuroprotective action of GOSPEL was further validated in a model of NMDA
excitotoxicity in vivo (26).
Furthermore, increased levels of oxidative stresses can promote GAPDH
aggregation in the cytoplasm, which seems to be associated with cell death (Fig. 1)
(30,31).  Oxidative stress in vitro elicits the formation of disulfide-bonded GAPDH
aggregates, which in turn results in the production of amyloid-like fibrils (30).  Similarly,
oxidative stress caused in vivo by methamphetamine, which produces massive oxidative
stress, induces the formation GAPDH aggregates in mouse brain.  In transgenic mice
overexpressing wild-type GAPDH methamphetamine accelerated GAPDH aggregation
and neuronal cell death (31).
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2. GAPDH in association with microtubules, vesicular trafficking, and the
cytoskeleton (membrane fusion)
GAPDH was one of the first glycolytic enzymes known to interact with tubulin
and actin to facilitate microtubule bundling and actin polymerization, respectively (Fig.
2) (5,32).  Serum deprivation, likely to be associated with oxidative stress, promotes the
association of GAPDH with the stress fibers (microfilament bundles) in NIH 3T3 cells
(33).  GAPDH-microtubule associations directly modulate the glycolytic activity and
quaternary structure of GAPDH by promoting the reversible dissociation of its tetrameric
isoform into glycolytically inactive monomeric molecules of GAPDH (34).  Furthermore,
catalytically active GAPDH may be transported within the cell via microtubule
treadmilling during a process that may allow it to couple signal-stimulated glycolysis
with the reorganization of the cytoskeleton  (Fig. 2) (5,32).
Multiple studies from different groups have demonstrated the participation of one
or more GAPDH isoforms in membrane fusion and trafficking in biological systems.  For
example, Robbins and colleagues (35) demonstrated that a mutation of GAPDH altered
membrane trafficking in Chinese hamster ovary cells.  The small GTPase Rab2 localizes
to vesicular tubular clusters (VTCs), which function as transport complexes carrying
cargo between the endoplasmic reticulum (ER) and the Golgi complex.  Tyrosine
phosphorylation of GAPDH by atypical protein kinase Cι (aPKC) is facilitated by Rab 2,
which increases phospho-GAPDH recruitment to VTCs.  This process plays an important
role for membrane trafficking between the ER and Golgi complex and for membrane
trafficking from VTCs (4,36,37).  A tyrosine kinase Src-mediated phosphorylation of
aPKC further facilitates protein associations of Rab2-Src-aPKC-GAPDH on VTCs (38),
9
and phospho-GAPDH promotes the interaction of the microtubules and motor proteins
with Rab2-generated vesicles (Fig. 2).  Thus, GAPDH might act as an adaptor or
scaffolding protein that mediates vesicular trafficking between cellular compartments
(Fig. 2) (39).  Similarly, GAPDH increases the interaction of the microtubules with N-
myrisotylated p22, an EF-hand Ca2+-binding protein, which facilitates microtubule-
membrane interactions (40).  Moreover, enzymatically active GAPDH has been
demonstrated to be necessary for fast axonal transport.  Scaffolding of GAPDH to
vesicles via Huntingtin allows vesicular GAPDH the capacity to provide ATP within
close proximity of transport vesicles (41).  The ATP generated by GAPDH fuels the
molecular motors for fast axonal transport over long distances, in a mitochondrial
independent manner.
GAPDH isoforms and/or posttranslational modifications of GAPDH have been
demonstrated to play a critical role in membrane fusion.  Resolution of GAPDH isoforms
by GTP-affinity and Mono Q chromatography has demonstrated that tetramers of
glycolytically inactive isoforms of GAPDH catalyze fusion of plasmenylethanolamine
containing vesicles (3).  GAPDH catalyzed membrane fusion was inhibited by
monoclonal antibodies against GAPDH, but not by koningic acid, a known inhibitor of
GAPDH glycolytic activity.  In vitro studies on the rate of fusion catalyzed by
glycolytically inactive isoforms of GAPDH suggest that GAPDH is capable of driving
fusion of synaptic vesicles with the presynaptic membrane at rates observed in vivo (3).
This isoform of GAPDH was not fully described in the studies mentioned; therefore one
or several posttranslational modifications of GAPDH could be involved in regulating
membrane fusion.  In deed, tubulin modulates GAPDH-catalyzed membrane fusion and
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phosphorylation of GAPDH via aPKC has been reported to counteract tubulin-mediated
inhibition of GAPDH-catalyzed membrane fusion (36,42).  Recent studies have
demonstrated that posttranslational deamidation of GAPDH by transglutaminase 2
increased localization of GAPDH to the plasma membrane and regulated membrane
fusion (43).  Glutamine to glutamate mutations of one to seven of the glutamines present
on GAPDH suggests that posttranslational deamidation of multiple but not specific
glutamines might be to sufficient to regulate membrane fusion.  These studies suggest
that the functional roles of GAPDH in cytoskeletal reorganization, membrane fusion and
vesicular trafficking are tightly regulated via posttranslational modifications to small
pools of GAPDH that are restricted to very limited subcellular locations.
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3. GAPDH in the mitochondria
At basal conditions the levels of GAPDH in the mitochondria are relatively low.
However, mitochondrial GAPDH levels are rapidly elevated when cells are exposed to
serum deprivation and DNA-damaging agents (44).  Previous studies have also
demonstrated that rotenone, a common mitochondrial complex I inhibitor, induces
enrichment of cytosolic GAPDH to nuclear and mitochondrial fractions (45).  Analysis of
GAPDH within these subcellular fractions revealed disulfide-bonded GAPDH dimers or
oligomers.
When GAPDH is expressed exogenously, a pool of GAPDH is translocated to the
mitochondria where it induces pro-apoptotic mitochondrial membrane permeabilization
(MMP) via an association with the voltage-dependent anion channel 1 (VDAC1) (44).
Studies with isolated mitochondria suggest that dimers and tetramers of GAPDH interact
with VDAC1.  Exogenous expression of GAPDH in the mitochondria cause loss of the
inner transmembrane potential, matrix swelling, permeabilization of the inner-
mitochondrial membrane, and the release of two pro-apoptotic proteins, cytochrome c
and apoptosis-inducing factor (Fig. 3) (44).
In contrast, another study reports that GAPDH participates in recovery from
mitochondrial outer-membrane permeabilization (MOMP) (46).  In this scenario,
GAPDH protects cells from death following MOMP, in the absence of caspase activation
(Fig. 3).  Here GAPDH may provide enough ATP to maintain the mitochondrial
membrane potential via the F0F1 ATPase, helping to counteract the effects of the
energetic collapse, thereby promoting cell survival.  Alternatively, stabilization of
activated Akt by overexpression of GAPDH indicates that GAPDH sustains Akt activity
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and leads to phosphorylation of FoxO, Bcl-6 downregulation and expression of Bcl-xL
(47).  Expression of Bcl-xL allows recovery of some mitochondria from MOMP and
promotes cell survival.
Protection from mitochondria-mediated cell death is also accomplished by
elimination of damaged mitochondria through mitophagy.  Cardiomyocytes exposed to
ischemia and reperfusion or reoxygenation (I/R) injury exhibit translocation of GAPDH
in association with mitophagy.  In a cell culture model and whole hearts, I/R was shown
to induce translocation of a catalytically inactive GAPDH isoform to the mitochondria
(48).  I/R induced translocation of GAPDH to the mitochondria is dependent on the
absence of phosphorylation at threonine residue 246 on GAPDH (48).  Inhibition of
protein kinase C δ (PKCδ) demonstrated that a GAPDH/ PKCδ signaling switch
regulates GAPDH-driven mitochondrial elimination via phosphorylation at T246 (48).
 Together, these studies demonstrate that GAPDH translocates to and regulates
cellular processes in association with the mitochondria.  However, for most cases it
remains unclear which specific posttranslational modifications play a role in regulating
translocation of GAPDH to the mitochondria or to specific mitochondrial proteins.
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4. GAPDH in the nucleus
We reported that a small pool of GAPDH is translocated to the nucleus upon
exposure to stressors and participates in cell death/dysfunction (12) with other groups
also replicating this observation (10,49-56).  This indicates that GAPDH may act as a
relay molecule between cellular compartments during cellular stress.  The signal is
conveyed by GAPDH that is S-nitrosylated by NO at active site Cys-150, allowing
GAPDH to bind to Siah1 (an E3 ubiquitin ligase), leading to nuclear translocation of the
GAPDH-Siah1 complex (Fig. 4) (6).  It seems that the nuclear localization signal on
Siah1 drives translocation of the GAPDH-Siah1 protein complex, probably while
maintaining the tetrameric structure of GAPDH.  Stabilized Siah1 together with S-
nitrosylated GAPDH facilitates ubiquitination and degradation of the nuclear co-
repressor N-CoR (6,57).  Further studies have also shown that nuclear translocated
GAPDH is further acetylated at Lys-160 by the histone acetyltransferase p300/CBP via
direct protein interaction, which in turn stimulates the catalytic activity of p300/CBP.
This nuclear event leads to the acetylation of downstream targets, including the tumor
suppressor p53 (Fig. 4) (58).  In the nucleus, nitrosylated GAPDH transfers its nitric
oxide to sirtuin-1 (SIRT1), histone deacetylase-2 (HDAC2) and DNA-activated protein
kinase (DNA-PK), thereby regulating the activity of nuclear proteins via
transnitrosylation (59). Through these mechanisms, the nuclear GAPDH-Siah1 complex
may regulate gene expression via degradation of transcriptional coregulatory proteins and
by modulating histone modifications, which may result in cell death, cellular dysfunction
or stress response.
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GAPDH was shown to co-immunoprecipitate with promyelocytic leukemia
protein (PML) and co-localize in a subset of nuclear bodies (Fig. 4) (60).  The
localization of PML and GAPDH to the same nuclear bodies is reportedly dependent on
the presence of RNA (60).  Since disruption of PML bodies reduces apoptosis in acute
promyelocytic leukemia and GAPDH induces apoptotic neuronal death, the GAPDH-
PML interaction may be involved in the regulation of cell death.  During hyperglycemia-
induced oxidative stress, poly (ADP-ribose) polymerase -1 (PARP-1), a DNA-repair
enzyme that is activated by severe DNA damage, regulates GAPDH activity by
poly(ADP-ribosyl)ation (Fig. 4) (61).  Inactivation of GAPDH via ADP-ribosylation
elicits greater cellular energy deficits and accelerates cell death.  Through this process,
GAPDH is believed to not only relay stress signals but also shuttle the generation of ATP
to cells responsible for repairing and/or removing dead or dying cells, such as those
surrounding ischemic tissue (62).
Nuclear GAPDH also has various functions unrelated to cell death.  The
correlation of increased uracil DNA glycosylase (UDG) activity with an increase in cell
cycle-regulated expression of monomeric GAPDH suggests that this multifunctional
molecule also plays an important role in DNA repair (Fig. 4) (63,64).  The cell-cycle
dependent expression of GAPDH in this study suggests that GAPDH has selective
functions at specific phases in the cell cycle.  GAPDH directly interacts with SET nuclear
oncogene, a molecule that inhibits cyclinB-cdk1 activity.  GAPDH-SET interaction
reverses the inhibitory effects of SET leading to an advanced cyclin B-cdk1 activity peak,
increased mitosis, and acceleration of the cell cycle (Fig. 4) (65).  In HeLa cells,
monomeric nuclear GAPDH associates with DNA as a component of the multicomplex
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Oct-1 coactivator (OCA-S) and stimulates expression of Histone 2B during S-phase (66).
Monomeric nuclear GAPDH acts as a redox sensor that regulates Histone 2B
transcription in a NAD+/NADH redox-dependent manner (Fig. 4) (67).  GAPDH-NAD+
association is required for Oct-1-mediated gene transcription.  O-linked N-
acetylglucosamine modifications of GAPDH (O-GlcNAcylation mainly on Thr227) are
able to disrupt the tetrameric form of GAPDH, enabling its nuclear translocation (68).
Thus, it may be important to explore whether O-linked N-acetylglucosamine
modifications may underlie roles of monomeric nuclear GAPDH.
GAPDH can also physically interact with apurinic/apyrimidinic endonuclease
(APE1), an essential enzyme that functions in the base excision DNA repair pathway to
process spontaneous and drug-induced abasic or apurinic/apyrimidinic sites, as well as, to
regulate the redox state of a number of transcriptional factors (Fig. 4) (69).  GAPDH
reactivates the endonuclease activity of APE1 by converting the oxidized APE1 to the
reduced form, restoring its ability to cleave abasic sites.  Nuclear GAPDH also plays a
role in maintaining and protecting telomeric DNA from rapid degradation (Fig. 4)
(70,71).
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5. Significance of multifunctional roles for GAPDH
Several distinct pools of GAPDH appear to sense intra- and extracellular stressors
via posttranslational and/or conformational changes and activate downstream pathways to
maintain homeostasis or promote cell death (summarized in Table. 1).  The prominent
expression of GAPDH in the cytosol may allow it to function efficiently as an
intracellular sensor capable of directly relaying signals to various organelles, such as the
nucleus.  GAPDH functions as a double-edged sword capable of facilitating the
completion of an apoptotic event or regulating the recovery from an insult, such as that
seen following MOMP in the mitochondria.  Of note, apoptotic cell death can contribute
to the maintenance of homeostasis at the organism level.  At the cellular level the
multifunctional roles of GAPDH maintain homeostasis within subcellular niches.
Glycolytic enzymes function in a well-coordinated manner, and some of them, such as
GAPDH and aldolase, form protein-protein complexes (72).  In analogy to GAPDH,
other glycolytic enzymes may have multiple roles and function as intracellular sensors.
The relationship of GAPDH with other glycolytic enzymes and their roles beyond
glycolysis may be an interesting subject to be studied in the future.  GAPDH is
evolutionally well preserved.  How did GAPDH acquire such a wide range of cellular
roles during the evolution?  This may be an interesting question to address in regard to
homeostatic regulation in organisms.
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6. Medical implications and future perspectives
Participation of GAPDH in multiple pathways of homeostatic regulation indicates
that this molecule may also play a role, when it is disturbed, in the manifestation of
certain diseases.  Accumulating evidence suggests that nuclear GAPDH may be involved
in several neurodegenerative disorders (73).  Nuclear GAPDH has been found in
fibroblasts and in postmortem brains from patients with polyglutamine diseases (such as
Huntington’s disease or dentatorubral-pallidoluysian atrophy) (74,75), Parkinson’s
disease (56), and Alzheimer’s disease (53,76).  Some studies suggest that GAPDH
interacts with β-amyloid peptides, mutant huntingtin, the androgen receptor, and
atrophin-1 (77-81).  Functional analyses have demonstrated that GAPDH negatively
affects the stability of SCN1A mRNA encoding the voltage-gated sodium channel α-I
subunit involved in Dravet syndrome (82).  In an experimental model of brain ischemia,
accumulation of nuclear GAPDH is observed (55).  More recently, a mouse model for
neuropsychiatric illness expressing a putative dominant-negative disruption in
schizophrenia 1 (DN-DISC1) was shown to have augmented GAPDH-Siah1 binding in
the frontal cortex (83).  Augmentation of this oxidative stress-associated cascade in this
mouse model suggests that the GAPDH-Siah1 pathway may also underlie cognitive and
motivational impairments observed in major mental illnesses.
Moreover, promising pharmacological evidence supports the notion that nuclear
GAPDH plays an important role in cell dysfunction and death.  Deprenyl, a classic
monoamine oxidase B (MAO-B) inhibitor, used for symptomatic amelioration in patients
with Parkinson’s disease also blocks GAPDH-Siah1 binding and reduces nuclear
translocation of GAPDH and cell death (84-87).  Rasagiline, another MAO-B inhibitor
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was also shown to have neuroprotective effects in ethanol-induced cell death mediated by
a novel GAPDH-MAO-B pathway (88,89).  Some structural derivatives of deprenyl, even
those lacking the inhibitory action on MAO-B, are also neuroprotective (84-87,90-92).
Among them, TCH346 shows neuroprotective action largely via blockade of GAPDH-
Siah1 binding and nuclear translocation of the GAPDH-Siah1 protein complex (93).  To
the contrary, saframycin, an antiproliferative agent for the treatment of leukemia- and
tumor-derive cells is capable of forming a ternary complex with GAPDH and DNA to
induce cytotoxic effects (94).  Further understanding of GAPDH may aid in the
development of novel therapeutic strategies for many disorders.
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Fig. 1.  GAPDH in the cytoplasm: Glycolytic enzyme, GAPDH, catalyzes the conversion of
glyceraldehyde-3-phosphate (G3P) into 1,3-biphosphoglycerate (1,3-BPG).  GAPDH can undergo different
posttranslational modifications, which may determine some of its non-glycolytic functions.  Under
conditions of cellular oxidative stress, GAPDH can undergo reversible S-thiolation (-SSG), a mechanism to
protect the glycolytic enzyme from irreversible oxidative inactivation and consequently redirecting the
metabolic flux from glycolysis to the pentose phosphate pathway to maintain an optimal NADPH/NADP+
ratio.  GAPDH contributes to local NADH+ and may regulate IP3R-mediated Ca2+ signaling.  Nitric oxide
stress also leads to reversible S-nitrosylation (-SNO) of cystine-150 of GAPDH that facilitates its binding to
Siah1, and results in translocation of the complex to the nucleus and irreversible sulphonation (-SO3H) of
GAPDH.  This cascade mediates cell death/dysfunction in a gain-of-toxic manner.  S-Nitrosylation of
GOSPEL augments binding of GOSPEL with GAPDH, competing with binding of Siah1 with GAPDH,
which is a cytoprotective mechanism against GAPDH-Siah1 cascade.  Exposure to oxidants can induce an
irreversible oxidation of cysteine residues that favor intermolecular disulfide bonds and the subsequent
formation of cytosolic aggregates of GAPDH.  This insoluble protein may ultimately promote cellular
dysfunction and cell death.
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Fig. 2. GAPDH in association with the cytoskeleton and vesicular transport: GAPDH is known to
interact with tubulin and actin, facilitating microtubule bundling and actin polymerization, respectively.
GAPDH may be transported within the cell via microtubule treadmilling.  GAPDH also plays an important
role in VTCs (vesicular tubular clusters) where phosphorylated GAPDH by atypical protein kinase Cι
(aPKC) is recruited.  This process plays an important role for membrane trafficking between the ER and
Golgi complex without requirement of GAPDH glycolytic activity.  A tyrosine kinase Src-mediated
phosphorylation of aPKC further facilitates protein associations of Rab2-Src-aPKC-GAPDH on VTCs, and
the phospho-GAPDH promotes the interaction of the microtubules and motor proteins with Rab2-generated
vesicles.
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Fig. 3. GAPDH in the mitochondria: GAPDH localized in the mitochondria has distinct functions in a
context-dependent manner.  GAPDH can bind with the voltage-dependent anion channel (VDAC), which
may promote the release of cytochrome c (CytC) and apoptosis-inducing factor (AIF), leading to apoptotic
cell death.  In stressed conditions, a decrease in mitochondrial membrane potential (ψm) leads to caspase-
independent cell death (CICD).  In this context, GAPDH can inhibit cell death by simultaneously
increasing ATP levels through glycolysis and stimulating autophagy-mediated clearance of permeabilized
mitochondria.
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Fig. 4. GAPDH in the nucleus: Oxidative modifications such as, S-nitrosylation of GAPDH, increase
binding to Siah1, which mediates its nuclear translocation.  GAPDH stabilizes Siah1 and facilitates Siah1-
mediated degradation of nuclear proteins such as, nuclear co-repressor (N-CoR).  Nuclear GAPDH is
acetylated by the p300/CREB-binding protein (CBP), which in turn stimulates the catalytic activity of
p300/CBP.  Consequently, downstream targets of p300/CBP, such as p53, can be activated and cause
cellular dysfunction.  In addition, GAPDH can undergo O-linked beta-N-acetylglucosamine glycosylation
(O-GlcNAcylation) at threonine residues, which also mediates its nuclear translocation.  Nuclear GAPDH
binding with PML is associated with cell death.  Nuclear GAPDH can participate in DNA repair,
regulations of gene transcription and cell cycle and turnover of telomeric DNA.  During oxidative stress,
PARP-1 may serve as an upstream regulator of nuclear GAPDH.
23
Table 1. Summary of posttranslational and/or conformational changes of GAPDH.
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Chapter II: Role of Apoptosis Signal-regulating Kinase 1 (ASK1) as an Activator of




Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) plays roles in both energy
maintenance and stress-signaling by forming a protein complex with seven in absentia
homolog 1 (Siah1).  Mechanisms to coordinate its glycolytic and stress cascades are
likely to be very important for survival and homeostatic control of any living organism.
Here we report that apoptosis signal-regulating kinase 1 (ASK1), a representative stress
kinase, forms a ternary complex with GAPDH and Siah1 and is able to phosphorylate
Siah1 at specific amino acid residues (T70/T74 and T235/T239).  Phosphorylation of
Siah1 by ASK1 triggers GAPDH-Siah1 stress-signaling and activates a key downstream
target, p300 acetyltransferase, in the nucleus.  This novel mechanism, together with the
established S-nitrosylation/oxidation of GAPDH at C150, provides evidence of how
GAPDH stress-signaling is finely regulated.  In addition, the present results imply
crosstalk between the ASK1 and GAPDH-Siah1 stress cascades.
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INTRODUCTION
Survival of living organisms is dependent on homeostatic control of energy
maintenance and a flexible response to environmental stressors (1-4).  In complex living
organisms, which are comprised of multiple cells and organs, survival of each cell and
elimination of damaged cells becomes important for homeostatic control (5-8).  Despite
the importance of this fundamental concept, the molecular machinery underlying these
mechanisms and their coordination are not fully understood.
A major mechanism for supplying cellular energy is glycolysis, in which glucose
is catabolized to pyruvic acid via several enzymatic reactions.  Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is a key enzyme in glycolysis that plays a major role
in cellular energy supply (9).  In addition to this classic role, GAPDH is involved in many
subcellular processes that include; DNA repair (10), membrane fusion and transport (11),
tRNA export (12) and cell death (13-19).  The functional diversity of GAPDH is largely
regulated by its subcellular localization and posttranslational modifications (20).
Recently studies have revealed that GAPDH can be oxidized and/or S-nitrosylated under
stress conditions.  Following this posttranslational modification GAPDH is then
translocated to the nucleus as a complex with Siah1, which has a strong nuclear
localization signal (21).  In the nucleus, GAPDH modulates several proteins, in particular
stimulating the catalytic activity of acetyltransferase p300/CREB binding protein (CBP)
that regulates transcription of various genes (22).  Therefore, GAPDH may modulate
homeostatic control by bridging energy supply (glycolytic pathway) to stress response
(GAPDH-Siah1 cascade), which is finely regulated by posttranslational modifications
(23-26).
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Apoptosis signal-regulating kinase 1 (ASK1) is a member of the mitogen-
activated protein kinase kinase kinase (MAPKKK) family.  Although cellular substrates
of ASK1 have not yet been fully studied, MAPKK4/7 (a kinase that phosphorylates JNK)
and MAPKK3/6 (a kinase that phosphorylates p38) are well-established substrates (27).
ASK1 is activated in response to oxidative stress, endoplasmic reticulum stress, and other
forms of cellular stress (28-30).  In addition, ASK1 plays pivotal roles in a wide variety
of cellular responses, which include, but are not limited to, apoptosis (31,32).
Dysregulation of the ASK1 signaling pathway is closely linked to various diseases, such
as cancer, cardiovascular diseases, diabetes, and neurodegenerative diseases including
polyglutamine-induced neurodegeneration and Parkinson’s disease (29,33-39).
The primary focus of the present study is to elucidate regulatory mechanisms of
the GAPDH-Siah1 pathway.  Here we report that ASK1 phosphorylates Siah1 and
critically modulates the GAPDH-Siah1 pathway via direct protein interactions.
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EXPERIMENTAL PROCEDURES
Chemicals, plasmids, and antibodies—All reagents were purchased from Sigma,
unless noted otherwise.  cDNA constructs for ASK1 were prepared as previously
published (40,41).  GST-tagged-ASK1, GAPDH and GST only constructs were cloned
into the pGEX-4T-1 vector.  GST-tagged-Siah1 constructs were cloned into the pGEX-
5X-2 vector.  HA- and FLAG-tagged-ASK1 constructs were cloned into the pcDNA3
vector.  Myc-tagged-Siah1 constructs were cloned into the pRK5 vector.  Myc-tagged-
Siah1 and its threonine to alanine (T to A) mutants were prepared using the Quick
Change site-directed mutagenesis kit according to the manufacturer’s protocol
(Stratagene).  Single mutants with threonine to alanine mutations are: M1, mutant with
T7A and T11A; M2, mutant with T70A and T74A; M3, mutant with T108A and T112A;
and M4, mutant with T235A and T239A mutations.  Double mutants are M1+M3 and
M2+M4.
[Siah1 mutant primers]
M1 (T7A and T11A):
Forward, 5’-GCCAGACTGCTGCAGCATTACCCGCCGCCACCTC-3’
M2 (T70A and T74A):
Forward, 5’-CGCCCCAAACTTGCATGTTGTCCCGCCTGCCGGGGC-3’
M3 (T108A and T112A):
Forward, 5’-TGTGAGATAGCTCTGCCGCACGCCGAAAAGGCAG-3’
M4 (T235A and T239A):
Forward, 5’-CGGCGATTGGCTTGGGAAGCCGCCCCTCGGTCT-3’
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Recombinant human GAPDH and human ASK1 [amino acids (aa) 649-946] were
purchased from Sigma and Cell Sciences, respectively.  The p38 inhibitor SB203580 and
JNK inhibitor SP600125 were purchased from Alexis Biochemicals.  Antibodies for
GAPDH (clones V18 and 6C5), Siah1 (P-18), Myc (9E10), p-Thr (H2) and p300 (C-20)
were from Santa Cruz Biotechnologies, p-ASK1(T845), p-p38, p-Jun, Ac-p300 (Lys
1499) were from cell signaling, HA (16B12) was from Clontech, GST (4C10) was from
Covance and FLAG (M5) from sigma, LDH, ASK1 and nuclear matrix protein p84
(5E10) were from Abcam.  HRP- conjugated mouse/rabbit antibodies were from GE
Healthcare, and goat HRP was from Santa Cruz.  γ-32P-ATP was from Perkin-Elmer.
Expression and purification of recombinant proteins—The pGEXT vectors
carrying GST-tagged-GAPDH, ASK1 (aa 1-940), ASK1 (aa 646-946) or WT Siah1 were
transformed into E. coli strain DH5α, and the proteins were purified as described (42).
Briefly, the E. coli DH5α were grown at 23°C for 2 h, induce with 0.1 mM IPTG for 4 h
or until OD reached 0.6, then cooled on ice water bath for 4 h.  Recombinant proteins
were purified from E. coli with glutathione sepharose beads.
Animals—C57/BL6 adult mice were purchased from Charles River.
Cell culture—HEK293 cells were grown in Dulbecco’s modified medium with
10% FBS and 1% pen-strep.  Polyfect (Qiagen) or Lipofectamine 2000 (Life
Technologies) were used for transfection of HEK293 cells.  Cells were harvested 48 h
after transfection.  To inhibit ASK1 activity, cells were pretreated with 10 µM NQDI for
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1 h prior to treatment with H2O2.  To activate a cellular stress response, cells were treated
with 1 mM H2O2 as indicated.
Co-immunoprecipitation (co-IP)—Cells were lysed in immunoprecipitation (IP)
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1 mg/ml BSA, protease
inhibitor cocktail), co-IPed, and Western blotted as previously described (21,22).  Briefly,
total cell lysates were incubated with primary antibodies overnigth, precipitated with
Trueblot beads (Rockland) and immunoprecipitates were analysed with SDS-PAGE,
followed by Western blotting.  For sequential co-IP studies, the first co-IP reactions were
performed with an anti-HA antibody and eluted with HA peptide at 30°C for 30 min.
Elutes were subjected to a subsequent co-IP with an anti-Myc antibody.  The final co-IP
was then subject to Western blot analysis with an anti-FLAG antibody.
Extraction of nuclear and cytoplasmic proteins—Nuclear and cytoplasmic
extracts were prepared using the Biovision nuclear/cytosol extraction kit according to the
manufacturer's instructions.
In vitro binding assays—ASK1-Siah1 and ASK1-GAPDH in vitro binding assays
were performed with equal molar concentrations of GST-tagged-ASK1, Siah1 and His-
tagged-GAPDH and incubated in binding buffer (0.1% NP40, 0.5 mM DTT, 10%
glycerol, 1 mM PMSF and 2 µg/ml aprotinin in PBS) for 2 h at 4°C.  To measure the
effects of GAPDH on ASK1-Siah1 binding, 0, 1 and 3 (GAPDH:Siah1) molar
concentrations of recombinant GAPDH, with respect to Siah1, were incubated in binding
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buffer, as mentioned below.  To obtain recombinant GAPDH and Siah1 without the GST
tag, GSH sephorose bounded protein was released via thrombin digestion, dialyzed in
Slide-A-Lyzer dialysis cassettes (Pierce) and protein purity was analyzed by Western
blot.  All in vitro binding assays were done by GST pull-down via incubation with GSH
sepharose beads (50% slurry) for 1 h, the samples were centrifuged at 4000 rpm for 1
min, washed three times in binding buffer, and resuspended in LDS sample buffer
(Invitrogen) with 5% β-mercaptoethanol (Sigma) and then heated at 95°C for 5 min.
Western blot analysis of the protein precipitates were done using anti-GAPDH, Siah1,
and GST antibodies.
In vitro kinase assay—In vitro phosphorylation assays were performed by
incubation of recombinant Siah1, GAPDH and GST with or without human recombinant
ASK1 (aa 649-946) protein (Cell Sciences) in kinase buffer (4 mM MOPS, pH 7.2, 2.5
mM β-glycerophosphate, 1 mM EDTA, 4 mM MgCl2, 0.05 mM DTT, 40 ng/µl BSA,
PIC1 and 2 (Sigma), and 10 mM γ-32P-ATP) at 30°C for 30min.  In vitro phosphorylated
proteins were subjected to SDS-PAGE and examined by autoradiography at -80°C with
intensifying screen.
    p38/JNK experiments—HEK293 cells expressing HA-GAPDH, Myc-Siah1, and
HA-ASK1 were treated with 20 µM p38 inhibitor (SB203580) or JNK inhibitor
(SP600125) for 1 h.  Cell lysates were subjected to co-IP followed by Western blot as
previously described (21,22).
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 Statistical analysis—Two-group analysis was performed by t-test (paired or
unpaired as appropriate).  A value of p< 0.05 is considered significant. All data was
obtained from the results of three or four independent experiments.  Optical density of
immunoreactivity in Western blotting was obtained using Image J software.
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RESULTS
GAPDH and Siah1 bind to ASK1 and form a ternary complex in cells—GAPDH-
Siah1 and ASK1 have been reported to independently play roles in several pathological
brain conditions, and are commonly shown to be key stress mediators (26,31,43-45).
Thus, we hypothesized that Siah1 and GAPDH might interact with ASK1 at the
molecular level.  To address this question, we examined mouse brain lysates and
observed endogenous protein interactions of ASK1-Siah1, ASK1-GAPDH and GAPDH-
Siah1 by co-IP (Fig. 1A).  Since ASK1 and GAPDH are both well-established sensors of
oxidative stress we hypothesized that oxidative stress may promoter the formation of a
ternary complex among this three molecules.  To test whether or not ASK1, Siah1 and
GAPDH formed a ternary complex, we performed sequential co-IPs on cell lysates from
HEK293 cells expressing ASK1, Siah1 and GAPDH and observed ASK1-Siah1-GAPDH
ternary complex formation is induced by treatment with H2O2 (Fig. 1B, upper panel).
Previous studies have reported stimulation of ASK1 activity by H2O2 (46).  To determine
if H2O2-stimulated ASK1 activity may be associated with ternary complex formation we
measured ASK1 activity via phosphorylation of ASK1 at T845 and demonstrated that
ASK1 activity correlated with ASK1-Siah1-GAPDH ternary complex formation (Fig. 1B,
lower panel).  These results suggest that ASK1, Siah1 and GAPDH form a ternary
complex in response to extracellular stressors.
Direct ASK1-Siah1 binding and modulation by GAPDH in vitro—GAPDH and
Siah1 are known to bind directly (21).  To characterize the interaction of Siah1 and
GAPDH with ASK1 we purified recombinant proteins for in vitro binding studies.
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Incubation of recombinant Siah1 together with glutathione S-transferase (GST) or GST-
tagged-ASK1 (aa 1-940) demonstrated that Siah1 binds directly to the N-terminal region
of ASK1 (Fig. 2A).  In contrast, incubation of recombinant GAPDH together with GST or
GST-tagged-ASK1 indicated that GAPDH does not directly to ASK1 in vitro at least
under this condition (data not shown).  To test whether GAPDH may modulate ASK1-
Siah1 binding we performed in vitro binding assays with recombinant Siah1 and ASK1
(aa 1-940) in the presence of increasing amounts of GAPDH.  These studies
demonstrated that a three molar equivalent of GAPDH augmented ASK1-Siah1 direct
binding (Fig. 2B).  ASK1 (aa 1-940) contains the ASK1 kinase domain (aa 646-946) (27).
To determine if Siah1 binds within the kinase domain we conducted in vitro binding
studies with recombinant Siah1 and fragments of the ASK1 kinase domain and
demonstrated that Siah1 binds to ASK1 fragment aa 646-846 of the kinase domain three
times more when compared to that of aa 646-946 (Fig. 2C).  Comparison of Siah1
binding with ASK1 fragment aa 646-946 and aa 746-946 indicates that the aa 696-746
region is critical for binding with Siah1 (Fig. 2C).  In contrast, Siah1 binding to ASK1
fragment aa 646-846 compared to the fragment aa 646-896 indicates that the aa 846-896
region may have an inhibitory effect (Fig. 2C).  The notion of these positive and
inhibitory domains can account for the overall results.
ASK1 phosphorylates Siah1 in cells and in vitro—Given that Siah1 directly binds
within the kinase domain of ASK1, we hypothesized that Siah1 might be a novel
substrate of ASK1 phosphorylation.  To investigate whether ASK1 could phosphorylate
Siah1 in cells, we stimulated ASK1 activity by treating HEK293 cells expressing ASK1
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and Siah1 with H2O2 and observed augmented Siah1 phosphorylation in an ASK1-
activity dependent manner (Fig. 3A).  Based on these results we hypothesized that ASK1
may directly phosphorylate Siah1, to address this question we conducted phosphorylation
studies using recombinant proteins in vitro.  Phosphorylation of GST-tagged Siah1, but
not GST, was observed when Siah1 was incubated with the constitutively active kinase
domain of ASK1 (aa 646-946) (Fig. 3B).  To assertain that phosphorylation of Siah1 was
indeed mediated by ASK1 we conducted in vitro phosphorylation studies in the presence
of NQDI-1 (an specific inhibitor of ASK1) and observed that ASK1 inhibition reduced
Siah1 phosphorylation (Fig. 3C).
Since we had shown that GAPDH facilitated ASK1-Siah1 binding, we
hypothesized that GAPDH may also augment phosphorylation of Siah1.  Therefore, we
conducted additional in vitro phosphorylation studies in the presence of increasing
amounts of GAPDH.  These studies revealed that in the presence of the kinase domain of
ASK1 (aa 646-946) GAPDH did not modulate phosphorylation of Siah1 (Fig. 3D).
ASK1 phosphorylates Siah1 at specific phosphorylation motifs—Since ASK1 has
been reported to phosphorylate substrates carrying the (S/TxxxS/T) consensus motif
(47,48), we examined the amino acid sequence of Siah1 and identified four potential
phosphorylation sites which we designated M1, M2, M3, and M4, respectively (Fig. 4A).
To characterize the ASK1 phosphorylation sites on Siah1, we generated mutants of Siah1
with point mutations (threonine to alanine substitutions) at each consensus sequence and
examined how these mutations affected phosphorylation of Siah1 by ASK1 via in vitro
kinase assays (Fig. 4B).  Amino acid substitution at M2 led to significant decreases in the
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phosphorylation of Siah1 by ASK1.  However, Siah1 phosphorylation by ASK1 was
reduced the most when we introduced mutations at both M2 and M4 (M2+M4) (Fig. 4B).
These data indicate that M2 (T70/T74), and M4 (T235/T239) together are the critical and
may function synergistically to facilitate phosphorylation by ASK1.
ASK1 augments Siah1 levels and GAPDH-Siah1 binding in cells—We next
addressed whether ASK1 modulates GAPDH-Siah1 signaling.  Thus, we introduced
wild-type (WT) ASK1, kinase-dead (KD) ASK1 that was generated with one amino acid
substitution at 709 (K709M), and constitutively active (CA) ASK1 (aa 649-1375) in cells,
respectively (41).  We then examined how these distinct forms of ASK1 affected
GAPDH-Siah1 binding.  We previously reported that sodium nitroprusside (a nitric oxide
donor) could affect GAPDH-Siah1 binding by S-nitrosylation of GAPDH (21), which
was used as a reference of the binding change.  Introduction of WT ASK1 dramatically
augmented GAPDH-Siah1 binding, which was considerably greater than the change
elicited by sodium nitroprusside in total cell lysates (Fig. 5A, lower panel).  When kinase
activity of ASK1 was selectively reduced (KD ASK1), such augmentation was also
reduced.  Consistent with this observation, introduction of CA ASK1 also dramatically
augmented GAPDH-Siah1 binding (Fig. 5A, upper panel).  Augmention of Siah1 levels
was observed in an ASK1 kinase dependent manner (Fig. 5A).  To ascertain that
augmentation of GAPDH-Siah1 binding was indeed regulated by ASK1 activity we
pretreated HEK293 cells with NQDI-1, a specific ASK1 inhibitor, before exposing cells
the H2O2.  Inhibition of ASK1 reduced endogenous GAPDH-Siah1binding induced by
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H2O2 (Fig. 5B).  These results suggest that ASK1, especially its kinase activity, is critical
for augmenting Siah1 levels and GAPDH-Siah1 protein binding.
ASK1-induced GAPDH-Siah1 binding in cells is independent of p38 and JNK
signaling—We considered the possibility that increased GAPDH-Siah1 binding could be
affected by JNK and p38, two key kinases downstream of ASK1 (27).  To test this idea,
we used specific kinase inhibitors (SB203580 specific for p38 and SP600125 specific for
JNK) and examined the effects on GAPDH-Siah1 binding in the presence of exogenous
WT ASK1.  Neither SB203580 nor SP600125 affected ASK1-Siah1, ASK1-GAPDH or
GAPDH-Siah1 binding (Fig. 6A, B), suggesting that ASK1-induced GAPDH-Siah1
binding occurs independent to p38/JNK signaling.
ASK1 augments nuclear translocation of GAPDH and p300 acetylation in cells,
which is likely to be affected by ASK1 phosphorylation on Siah1—The major downstream
event of activated GAPDH-Siah1 stress signaling is nuclear translocation of the GAPDH-
Siah1 protein complex (21).  Thus, we questioned whether ASK1 might facilitate this
nuclear translocation, and tested the effects of WT or KD ASK1.  We observed robust
nuclear translocation of the GAPDH-Siah1 complex in the presence of exogenous WT
ASK1, whereas introduction of KD ASK1 did not elicit significant levels of GAPDH-
Siah1 nuclear translocation (Fig. 7A).
We further tested whether this translocation by ASK1 was related to
phosphorylation of Siah1.  In the presence of ASK1 the complex of GAPDH and mutant
Siah1 (M2+M4 mutant; lacking ASK1 phosphorylation sites) displayed significantly
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reduced nuclear translocation compared to the complex of WT Siah1 and GAPDH (Fig.
7B).
We then questioned whether these Siah1 mutations (M2+M4) critically affect
nuclear functions in ASK1-triggered GAPDH-Siah1 stress signaling.  Thus, we examined
GAPDH-p300 binding and acetylation of p300, which have been established as good
functional indicators for nuclear GAPDH (22).  Western blot analysis revealed a
significant decrease in p300-GAPDH binding and acetylation of p300, which can be
interpreted as a key consequence of reduced nuclear translocation of GAPDH in the
presence of the M2M4 Siah1 mutant (Fig. 7C).  These results suggest that
phosphorylation of Siah1 by ASK1 is likely to play a key role in the GAPDH-Siah1
signaling cascade and subsequent functional effects in the nucleus.
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DISCUSSION
Cellular signaling in response to stressors is crucial in homeostatic control and
survival of all organisms.  Thus, crosstalk among signaling cascades and their finely
tuned regulation are expected.  In the present study, we show that ASK1, a representative
stress kinase, regulates GAPDH-Siah1 signaling (Fig. 8).  Here we induce oxidative
stress with H2O2, a known physiological and pathophysiological stressor, to demonstrate
that ASK1, Siah1, and GAPDH form a ternary protein complex that is augmented under
oxidative stress and is likely to be the basis of this signal network.  We have identified
Siah1 is a novel substrate of ASK1, with T70/T74 and T235/T239, as the critical
phosphorylation sites on Siah1, at least in vitro.  Phosphorylation by ASK1 was found to
increase GAPDH-Siah1 binding, its nuclear translocation, and subsequent acetylation of
nuclear p300.
Thus far, a specific posttranslational modification of GAPDH (S-
nitrosylation/oxidation at C150) had been established as an initial trigger of GAPDH-
Siah1 signaling (21).  In the present study we show that specific posttranslational
modifications of Siah1, the other partner of this complex, can also be a trigger of this
cascade.  ASK1 is activated in response to various stressors, such as oxidative stress and
endoplasmic reticulum stress, it is likely that Siah1 is subsequently phosphorylated and
mediates stress signaling by forming a complex with GAPDH.  Thus, this study
establishes the notion that the GAPDH-Siah1 cascade is activated by more than one
mechanism in the presence of various cellular stressors.  This cascade is also inhibited by
at least two mechanisms: both interaction with a cytosolic protein GOSPEL (49) and a set
of deprenyl-related compounds (42).  It is likely that the GAPDH-Siah1 cascade, which is
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crucial for homeostatic control, has multiple mechanisms that regulate its initiation in
both positive and negative ways.  It will be interesting to clarify how these two distinct
posttranslational modifications (oxidation of GAPDH and phosphorylation of Siah1) are
coordinated under different types of stress.  Given that both ASK1 and GAPDH-Siah1
cascades are major routes of stress signaling, an important future question is to
understand how GAPDH-Siah1 can also influence ASK1.
Here we demonstrate that ASK1 and GAPDH-Siah1 co-mediate stress signaling
and activate p300.  It is known that p300 has multiple functions in different conditions:
for example, in the heart p300 activation can lead to heart hypertrophy mediated by
myocyte enhancer factor-2 (MEF2) (50), whereas in the brain p300 affects memory
function via cAMP response element-binding (CREB) (51).  Roles for stressors in these
conditions are appreciated, but further molecular mechanisms remain to be elucidated.
Thus, the generation of new conditional knockout mice or inducible transgenic models
targeting these molecules will be crucial to test context-dependent crosstalk of ASK1 and
GAPDH-Siah1.  As far as we are aware, such mice are not available at present.  Better
understanding of the crosstalk between these two stress cascades (ASK1 and GAPDH-
Siah1) may provide a more integrated and comprehensive picture of how our body
responds to stressors in a context-dependent fashion and how disturbances of such
mechanisms may lead to pathological conditions.
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Figure 1. Siah1 and GAPDH bind with ASK1 and form a ternary complex in cells. (A) ASK1-Siah1 and
ASK1-GAPDH binding in mouse brain extracts. Mouse brain extracts were immunoprecipitated (IPed)
with anti-Siah1 or anti-GAPDH antibodies and analyzed by Western blot with anti-ASK1, GAPDH, and
Siah1 antibodies. Input is total cell lysates for IP. (B) HEK293 cells expressing FLAG-ASK1, HA-GAPDH
and Myc-Siah1 were treated with 1mM H2O2 for 30 min to induce activation of ASK1 (lower panel). Cell
lysates were IPed in sequence with anti-HA and anti-Myc antibodies, respectively, and analyzed by
Western blot with an anti-FLAG antibody (upper panel). Input is the starting material for IP. Ternary
complex formation was quantified by densitometric analyses (t-test, *p<0.05, **p<0.01 versus no treatment
FLAG-ASK1).
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Figure 2. ASK1 directly binds to Siah1 and is modulated by GAPDH in vitro. (A) Recombinant GST-
ASK1 [amino acids (aa) 1-940] or GST were incubated with recombinant Siah1 in vitro and subjected to
GST pull-down, followed Western blot with an anti-Siah1 antibody. Input is the starting material for IP.
Arrow indicates GST-ASK1 (aa 1-940). (B) GAPDH facilitates ASK1-Siah1 binding in vitro. ASK1-Siah1
binding was assessed by incubating recombinant GST-ASK1 (aa 1-940), or GST with recombinant Siah1
and GAPDH protein at 0, 1 or 3 (GAPDH:Siah1) molar concentrations, followed by to GST pull-down.
Precipitates were analyzed Western blot with an anti-Siah1 antibody. Input is the starting material for IP.
ASK1-Siah1 binding was quantified by densitometric analyses (t-test, *p<0.05 versus Siah1 (without
GAPDH)). (C) Siah1 directly binds ASK1 within the kinase domain. Recombinant GST-ASK1 fragments
of the kinase domain or GST were incubated with recombinant Siah1 in vitro and subjected to GST pull-
down, followed by Western blotting with an anti-Siah1 antibody. Input is the starting material for IP.
Numerical values indicate ASK1-Siah1 binding quantified relative to GST-ASK1 (aa 646-946). Within
domain map black indicates critical binding domain and grey indicates potential inhibitory binding domain.
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Figure 3. ASK1 phosphorylates Siah1 in cells and in vitro. (A) Stress-induced phosphorylation of Siah1 in
cells.  H2O2 treatment induced ASK1 activity and Siah1 phosphorylation. (B) Phosphorylation of Siah1 by
ASK1 in vitro. (C) ASK1 inhibitor (NQDI-1) reduced direct Siah1 phosphorylation at both 2.5 µM and 25
µM concentrations. (D) In the presence of the ASK1 kinase domain GAPDH does not augment
phosphorylation on Siah1. In vitro phosphorylation assays were performed by incubation of recombinant
GST-Siah1 or GST with constitutively active GST-ASK1 (aa 646-946) in the presence of γ-32P-ATP.
52
Figure 4. ASK1 phosphorylated Siah1 at specific phosphorylation motifs. (A) Four consensus (S/TxxxS/T)
phosphorylation motifs for ASK1 in Siah1 protein: designated as M1, M2, M3 and M4. (C) M2+M4
mutant Siah1 shows a significant reduction of phosphorylation by ASK1 in vitro. Labeling with γ-32P-ATP
was carried out in vitro with recombinant GST-ASK1 (aa 646-946), along with several mutants of Siah1
(M1, M2, M3, M4, M2+M4 and M1+M3), followed by detection of Siah1 phosphorylation by
autoradiography. Input is GST-ASK1 (aa 646-946) and Siah1 in starting material. Siah1 phosphorylation
levels were quantified by densitometric analyses (t-test, *p<0.05 versus WT Siah1).
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Figure 5. ASK1 facilitates GAPDH-Siah1 binding in cells. (A) Upper panel, ASK1 augments GAPDH-
Siah1 binding in a kinase-dependent manner. Cell lysates of HEK293 cells expressing Myc-tagged wild-
type (WT) Siah1 together with HA-WT ASK1, kinase-dead (KD) ASK1, or constitutively active (CA)
ASK1, were IPed with an anti-GAPDH antibody and analyzed by Western blot with an anti-Myc antibody
(for Siah1). Input is the total cell lysates. Lower panel, Sodium nitroprusside (SNP, a nitric oxide donor)
elicits an augmented GAPDH-Siah1 binding. HEK293 cells expressing Myc-WT Siah1 were treated with
SNP, cell lysates were IP with an anti-GAPDH antibody and immunoprecipitates were analyzed by
Western blot with an anti-Myc (Siah1) antibody. Input is Myc-Siah1 in total cell lysates. Western blots
were quantified by densitometric analyses (t-test,  **p<0.01 and ***p<0.001 versus Mock). (B) ASK1
inhibitor NQDI-1 inhibits endogenous GAPDH-Siah1 binding. HEK293 cells were pretreated with 10 µM
NQDI-1 for 1 h prior to treatment with 1 mM H2O2. Whole cell lysate were Iped with an anti-Siah1
antibody and analyzed by Western blot with an anti-GAPDH antibody. Input is the total cell lysates.
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Figure 6. ASK1-Siah1, ASK1-GAPDH and GAPDH-Siah1 binding is independent of p38 and JNK
signaling. ASK1-Siah1, ASK1-GAPDH and GAPDH-Siah1 binding occurs independent of p38 and JNK
activation. (A) ASK1-Siah1, ASK1-GAPDH and GAPDH-Siah1 binding was assessed in lysates from
HEK293 treated with 10 µM p38-specific inhibitor (SB203580) followed by IP and Western blot with
indicated antibodies. Input is expression of HA-ASK1, HA-GAPDH and Myc-Siah1 in total cell lysates.
(B) ASK1-Siah1, ASK1-GAPDH and GAPDH-Siah1 binding was assessed in HEK293 cells treated with
10 µM JNK-specific inhibitor (SP600125) followed by the IP and Western blot with indicated antibodies.
Input is expression of HA-ASK1, HA-GAPDH and Myc-Siah1 in total cell lysates.
55
Figure 7. ASK1 augments nuclear translocation of GAPDH and p300 acetylation in cells, likely being
mediated by ASK1 phosphorylation on Siah1. (A) ASK1 augments nuclear translocation of GAPDH in a
kinase-dependent manner. Effects of ASK1 kinase activity on nuclear translocation of GAPDH were
examined in HEK293 cells expressing HA-tagged WT or KD ASK1, followed by cellular fractionation and
Western blot quantification of GAPDH nuclear/cytoplasmic ratios. GAPDH signals were normalized by
LDH (a cytoplasmic marker) and P84 (a nuclear marker) (t-test, ***p<0.001 versus Mock). (B) M2 and M4
phosphorylation sites of Siah1 by ASK1 are critical to induce nuclear translocation of GAPDH. HEK293
cells expressing HA-WT ASK1 together with Myc-WT or M2+M4 mutant Siah1 were fractionated, and
GAPDH nuclear/cytoplasmic ratios in each subcellular fraction were quantified (*p<0.05 versus WT
Siah1). (C) M2 and M4 phosphorylation sites of Siah1 by ASK1 are required for acetylation of p300 and
p300-GAPDH interaction. Lysates of HEK293 cells expressing HA-WT ASK1 together with Myc-WT
Siah1 or M2+M4 mutant Siah1 were IP-ed with an anti-p300 antibody and analyzed by Western blot with
acetyl-p300-Lys1499 / acetyl-CBP-Lys 1535 (p300/CBPAc) and GAPDH antibodies. Input is endogenous
p300 and GAPDH in total cell lysates. Western blots were quantified by densitometric analyses (t-test,
*p<0.05 and **p<0.01 versus WT Siah1).
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Figure 8. ASK1 regulates the GAPDH-Siah1 stress-signaling cascade. Exogenous stressors activate ASK1
kinase activity, ASK1 phosphorylates Siah1, phosphorylation of Siah1 induces GAPDH-Siah1 binding, the
GAPDH-Siah1 complex translocates into the nucleus, in the nucleus GAPDH induces acetylation of p300.
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In this study we have identified ASK1 as a novel regulator of the
GAPDH-Siah1 stress-signaling cascade.  We found endogenous ASK1-GAPDH, ASK1-
Siah1 and Siah1-GAPDH binding in adult mouse brain lysates.  We show that upon
treatment with oxidative stress these protein-protein interactions are mediated by
formation of a ternary complex among ASK1, Siah1 and GAPDH.  Further
characterization of these protein interactions demonstated direct binding between ASK1
and Siah1, which was further augmented by GAPDH.  Although direct ASK1-GAPDH
binding was not observed in vitro, the observed augmentation in ASK1-Siah1 binding in
the presence of GAPDH suggests that GAPDH may function as a scaffolding molecule
between ASK1 and Siah1.  Furthermore, direct interaction between the kinase domain of
ASK1 and Siah1 suggested that Siah1 might be a substrate of ASK1.  Phosphorylation
studies and in vitro kinase studies demonstrate that stress-induced activation of ASK1 led
to increased phosphorylation of Siah1 and that the ASK1 kinase domain directly
phosphorylates Siah1.  A specific inhibitor of ASK1 (NQDI-1) is shown to decrease
Siah1 phosphorylation and further demonstrates that ASK1 induces direct
phosphorylation of Siah1.  Since GAPDH is capable of increasing ASK1(1-940)-Siah1
binding, but not Siah1 phosphorylation in the presence of the ASK1 kinase domain (646-
946), we hypothesized that a region within the 1-646 domain is essential for GAPDH
interaction.  Siah1 is identified as a novel substrate of ASK1 and the M2 and M4 sites on
Siah1 are demonstrated as two critical sites for phosphorylation by ASK1.  We found
GAPDH-Siah1 binding increases in an ASK1 kinase-dependent manner and that ASK1 is
a stronger trigger of GAPDH-Siah1 binding than the previously reported S-nitrosylation
of GAPDH.  Cellular fractionation studies demonstrate that nuclear translocation of
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GAPDH is augmented by ASK1 and that translocation of GAPDH is reduced in the
presence of the M2M4 mutant Siah1.  In the nucleus GAPDH was demonstrated to
induce acetylation of transcriptional co-activator CBP/p300, which was also reduced in
the presence of the M2M4 mutant Siah1.
Recognition of ASK1 as an activator of the GAPDH-Siah1 stress-signaling
cascade identifies ASK1, and the M2M4 sites on Siah1, as novel therapeutic targets to
reduce nuclear translocation of GAPDH.  ASK1 activation has predominantly been
associated with signaling cascades that ultimately lead to cell death.  However, recent
studies have reported that activation of ASK1 promotes differentiation and survival of
neuronal and non-neuronal cells (1-3).  Similar to GAPDH, ASK1 may have opposing
functions that simultaneously regulate cell survival and cell death.  While inhibitors such
as NQDI-1 may inhibit GAPDH-Siah1 stress signaling, global inhibtion of ASK1 could
have detrimental side effects.  Therefore, developement of molecules that inhibit ASK1-
induced GAPDH-Siah1 stress-signaling by targeting the M2M4 sites might be a valuable
and more specific therapeutic strategy against diseases such as, cancer, cardiovascular
disease, neurodegeneration, ischemia and major mental illness.
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